Cargando…

Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Detalles Bibliográficos
Autor principal:	Saba, Nabil F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346538/ https://www.ncbi.nlm.nih.gov/pubmed/28348975 http://dx.doi.org/10.3389/fonc.2017.00031

Ejemplares similares

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
por: Fayette, Jérôme, et al.
Publicado: (2016)

Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab)
por: McKnight, Brooke N., et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
por: Saigal, Kunal, et al.
Publicado: (2014)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
por: Pogorzelski, Michael, et al.
Publicado: (2021)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker
por: Berszin, Michael, et al.
Publicado: (2022)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Transcriptomic study of the mechanism of anoikis resistance in head and neck squamous carcinoma
por: Guo, Chen, et al.
Publicado: (2019)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
por: Carinato, Hélène, et al.
Publicado: (2021)

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Razak, Albiruni R. Abdul, et al.
Publicado: (2023)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Exosomes in Head and Neck Squamous Cell Carcinoma
por: Xiao, Cheng, et al.
Publicado: (2019)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Hanemaaijer, Saskia H., et al.
Publicado: (2020)

Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Tousif, Devale, et al.
Publicado: (2020)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016)

Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
por: Van Gestel, Dirk, et al.
Publicado: (2020)

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Towards Photodynamic Image-Guided Surgery of Head and Neck Tumors: Photodynamic Priming Improves Delivery and Diagnostic Accuracy of Cetuximab-IRDye800CW
por: Bhandari, Chanda, et al.
Publicado: (2022)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pulp32jr2t1nh01aammofugft6